Median Technologies : Company Update and Forthcoming Milestones

Corporate Update

and Forthcoming

Milestones

Company Webcast

July 20th, 2023

FREDRIK BRAG

CEO AND FOUNDER

Disclaimer

• The information provided in this presentation pertaining to Median Technologies SA . ("Median" or the "Company"), its business assets, strategy and operations is for general informational purposes only and is not a formal offer to sell or a solicitation of an offer to buy any securities, options, futures, or other derivatives related to securities in any jurisdiction and its content is not prescribed by securities laws. Information contained in this presentation should not be relied upon as advice to buy or sell or hold such securities or as an offer to sell such securities. This presentation does not take into account nor does it provide any tax, legal or investment advice or opinion regarding the specific investment objectives or financial situation of any person. While the information in this presentation is believed to be accurate and reliable, Median and its agents, advisors, directors, officers, employees and shareholders make no representation or warranties, expressed or implied, as to the accuracy of such information and Median expressly disclaims any and all liability that may be based on such information or errors or omissions thereof. Median reserves the right to amend or replace the information contained herein, in part or entirely, at any time, and undertakes no obligation to provide the recipient with access to the amended information or to notify the recipient thereof.
• Neither Median nor any of Median's representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this presentation by you or any of your representatives or for omissions from the information in this presentation. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made by, third parties in respect of the matters discussed in this presentation.
• This presentation is intended only for persons who (i) have professional experience in matters relating to investments within the meaning of "investment professionals" as defined, (ii) to whom an invitation or inducement to engage in investment activity in connection with the issuance or sale of securities may be lawfully communicated to or caused to be communicated to (all such persons together being referred to as "Qualified Persons"). This presentation is intended for Qualified Persons only and cannot be given to persons who are not Qualified Persons. Any investment or investment activity to which this presentation refers is permitted for Qualified Persons only and will be denied to any other person.
• Certain information in this presentation and oral statements made in any meeting are forward-looking and relate to Median and its anticipated financial position, business strategy, events and courses of action. Words or phrases such as "anticipate," "objective," "may," "will," "might," "should," "could," "can," "intend," "expect," "believe," "estimate," "predict," "potential," "plan," "is designed to" or similar expressions suggest future outcomes. Forward-looking statements and financial projections include, among other things, statements about: our expectations regarding our expenses, sales and operations; our future customer concentration; our anticipated cash needs, our estimates regarding our capital requirements, our need for additional financing; our ability to anticipate the future needs of our customers; our plans for future products and enhancements of existing product or services; our future growth strategy and growth rate; our future intellectual property; and our anticipated trends and challenges in the markets in which we operate. Forward-looking statements and financial projections are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements and financial projections. Although we believe that the expectations reflected in the forward-looking statements and financial projections are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, level of activity, performance or achievements and there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking statements and financial projections.
• By their nature, forward-looking statements and financial projections involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking information will not occur, which may cause the Company's actual performance and financial results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements and financial projections. Important factors that could cause actual results to differ materially from expectations include, but are not limited to: business, economic and capital market conditions; the heavily regulated industry in which the Company carries on business; current or future laws or regulations and new interpretations of existing laws or regulations; legal and regulatory requirements; market conditions and the demand and pricing for our products; our relationships with our customers, developers and business partners; our ability to successfully define, design and release new products in a timely manner that meet our customers' needs; our ability to attract, retain and motivate qualified personnel; competition in our industry; competition; technology failures; failure of counterparties to perform their contractual obligations; systems, networks, telecommunications or service disruptions or failures or cyber-attack; ability to obtain additional financing on reasonable terms or at all; our ability to manage risks inherent in foreign operations; litigation costs and outcomes; our ability to successfully maintain and enforce our intellectual property rights and defend third party claims of infringement of their intellectual property rights; our ability to manage foreign exchange risk and working capital; and our ability to manage our growth. Readers are cautioned that this list of factors should not be construed as exhaustive.
• The forward-looking statements and financial projections contained in this presentation are expressly qualified by this cautionary statement. Except as required by law, we undertake no obligation to update or revise publicly any forward- looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Readers are cautioned not to place undue reliance on forward-looking statements or financial projections. Prospective investors should not construe the contents of this presentation as legal, tax, investment or other advice. All prospective investors should make their own inquiries and consult their own advisors as to legal, tax, investment, and related matters concerning an investment in the securities of the Company.

2	mediantechnologies.com | July 20, 2023

Early diagnosis saves lives

We are helping conquer cancer and fibrotic diseases by extracting powerful

clinical insights from patients' medical images

Our people	230+ highly qualified professionals in the
	US, Europe and China, 25+ nationalities
Our growth	Powered by proprietary AI, computer
	vision and signal processing technologies,
	strong KOL connections, and medical,
	scientific, technology partnerships.
	With iBiopsy®, our AI-powered imaging
	platform for the development of
	Software as Medical Device, we help
	clinicians to diagnose patients earlier. We
	intend to launch our iBiopsy® Lung
	Cancer Screening SaMD in the US
	in 2024.
	Our iCRO imaging solutions and advanced
	Imaging Lab offer help our 80+
Imaging	biopharma clients drive their oncology
Lab	clinical studies toward successful
	approval, using AI-driven image insights.

July 13, 2023: Successful Capital Increase

• €11.6 million capital increase subscribed by 25+ European institutional shareholders, and a tranche of retail investors, at a price of €4.70 per share.
• Agreement finalized for a €10 million convertible bonds issue at a fixed interest rate and with a fixed conversion price of €6.458, to be subscribed by long- term shareholder Celestial Successor Fund, LP.
• Subject to certain conditions, Median may draw the second tranche of the loan granted by the EIB for a further €10 million.

4	mediantechnologies.com | July 20, 2023

Company's financing

outlook extended until 2025

2023 & Beyond: Transformative Developments

AI Screening is about to transform lung cancer patient care pathway

• In the US, LDCT lung cancer screening has been reimbursed since 2015 by CMS and 14.5M are now eligible for imaging LCS
• EU countries have announced the launch of LCS programs in the coming years. European eligible population is 20M+
• A new CPT reimbursement code of $650 for quantitative CT tissue characterization is active
• The Lung Cancer Screening TAM is $10- 20bn for the US & EU and could double with Asia

AI imaging is changing the game for

the pharma industry

• Pharma companies are operating a stage shift to treat early-stage disease to increase chance of success
• AI Imaging is revolutionizing drug development through:
• • Cancer detection & characterization
  • Molecular status prediction
  • Response predictions / Companion diagnostics

5	mediantechnologies.com | July 20, 2023